|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
Reuters Market Eye - Shares in Sun Pharmaceutical Industries
Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.
"Bovina generated an annual sales of $82 million in 2012. Currently, Sun Pharma is the only generic player to have final approval for this product," brokerage Sharekhan said in a note on Wednesday.
More players would be able to sell the drug after its patent expiry on September 2, 2014, Sharekhan said.
(Reporting by Abhishek Vishnoi)